

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

GENPREX, Inc. (GNPX) – BUY Rated, \$3.0 PT

June 27, 2023

Jason H. Kolbert
Managing Director & Senior Analyst
jkolbert@dawsonjames.com

Vertex (VRTX-Not Rated) announced a strategic collaboration to support the manufacture of the company's portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with Type 1 diabetes. We view this news as positive for Genprex as the company has an innovative cell focused therapy in diabetes too.


Investment Highlights

Diabetes Program: The company has developed a gene therapy that is designed to transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system. The therapy utilizes a procedure in which an adeno-associated virus vector is endoscopically delivered to the pancreas to insert Pdx1 and MafA genes. GPX-002 for T1D uses a glucagon promoter in alpha cells. GPX-003 for T2D uses an insulin promoter in beta cells. **The planned phase 1 trial represents the first-ever gene therapy tested in humans for diabetes.** In vivo, preclinical studies (mice), have shown that GPX-002 restored normal blood glucose levels for an extended period. Research collaborators at the University of Pittsburgh presented data in non-human primates highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) which was held February 22-25 in Berlin, Germany.

The presentation: "Pancreatic Intraductal Infusion of Adeno-Associated Virus (AAV) to Treat Non-Human Primates in a Toxin-Induced Diabetes Model," reported results from eight non-human primates (NHPs) with toxin-induced diabetes after streptozocin administration. They received a novel infusion process that used an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. The statistically significant study results show that post-infusion of the AAV engineered construct, the eight NHPs had "decreased insulin requirements (p<0.001); increased c-peptide levels (p<0.05); and improved glucose tolerance compared to baseline (p<0.05) with one demonstrating reestablished normoglycemia. Immunohistochemistry revealed insulin and glucagon staining, which suggest the formation of insulin-producing cells."

Valuation: We project our model out to 2033. We apply a 30% risk cut to our projected revenues in our product model in addition to our 30% risk rate applied in our Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models. We use a fully diluted out-year share count, assuming multiple raises. The result is equal-weighted, averaged, and rounded to the nearest whole number to derive our 12-month projected price target of \$3.00. We note that as the company established proof of concept as a result of clinical trial data, the risk rate (r) is reduced, and valuation rises.

Risks to our thesis include: 1. Regulatory Approvals; 2. Clinical Science 3. Adoption Rates 4. The competitive landscape. 5. Intellectual Capital 6. Dilution.



Source: Genprex

Current Price		\$0.74
Price Target		\$3.00
Stock Data		
52-Week Range	\$0.72 -	\$2.67
Shares Outstanding (mil.)		52.0
Market Capitalization (mil.)		\$39
Enterprise Value (mil.)		\$20
Debt to Capital		0%
Book Value/Share		-
Price/Book		3.1
Average Three Months Trading Volume (K)		89
Insider Ownership		2.4%
Institutional Ownership		11.5%
Short interest (mil.)		3.9%
Dividend / Yield		\$0.00/0.0%



Risks to our thesis include 1. Regulatory Approvals; 2. Clinical Science 3. Adoption Rates 4. The competitive landscape 5. Intellectual Capital 6. Dilution.

- **Regulatory Approvals.** The company's products require regulatory approvals, and there can be no assurances that the requirements to achieve these approvals can be met.
- **Clinical Science:** The company will need to demonstrate its therapeutics work and are safe and comparable or better versus the existing standard of care.
- **Adoption Rates:** There are no assurances that our projected market share can be met. A combination of factors from efficacy, positioning in the competitive landscape, pricing and reimbursement are factors in driving decision-makers to select the product for their practices and patients.
- **The Competitive Landscape & IP.** The company does have intellectual property and knows how to protect the utility of its devices and software; however, we expect that the technology cycle will be competitive, and the company may face competition from well-financed competitors who are already in position in the target markets.
- **Dilution:** The company is likely to incur losses for the foreseeable future until it is able to generate sufficient revenue from product sales. Our model assumes a rising share count. There can be no assurances that the company can successfully raise the capital required to execute its business strategy.

Exhibit 1. Income Statement


GENPREX: Income Statement ('000s)																
000 : YE December 31	2022A	1Q23A	2Q23E	3Q23E	4Q23E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E
Product sales	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Oncology	-	-	-	-	-	-	-	-	-	-	-	-	75,000	200,000	350,000	1,000,000
Diabetes	-	-	-	-	-	-	-	-	-	-	-	-	75,000	200,000	350,000	1,000,000
Total Product Sales	-	-	-	-	-	-	-	-	-	-	-	-	150,000	400,000	700,000	2,000,000
Costs and Expenses:																
COGS													45,000	112,000	175,000	500,000
COGS %													30%	28%	25%	25%
Depreciation	26	4														
Research and Development	11,510	5,310	3,453	3,453	1,596	13,812	16,575	19,889	23,867	28,641	34,369	27,495	26,120	26,643	27,176	27,719
General and Administrative	12,295	3,957	3,105	3,105	2,252	12,418	12,542	12,668	12,794	12,922	13,051	15,009	27,017	27,287	27,560	27,835
Total Operating Expenses	23,831	9,271	6,558	6,558	3,848	26,230	29,117	32,557	36,662	41,563	47,420	42,504	53,137	53,929	54,735	55,554
Loss from Operations	(23,831)	(9,271)	(6,558)	(6,558)	(3,848)	(26,230)	(29,117)	(32,557)	(36,662)	(41,563)	(47,420)	(42,504)	96,863	346,071	645,265	1,944,446
Other Expense																
Interest Income	90	68	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Other Expense	90	68	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Loss	(23,741)	(9,203)	(6,558)	(6,558)	(3,848)	(26,230)	(29,117)	(32,557)	(36,662)	(41,563)	(47,420)	(42,504)	96,863	346,071	645,265	1,944,446
	-	-	-	-	-	-	-	-	-	-	-	-	9,686	51,911	129,053	700,000
Tax Rate	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	10%	15%	20%	36%
GAAP Net Income (loss)	(23,741)	(9,203)	(6,558)	(6,558)	(3,848)	(26,230)	(29,117)	(32,557)	(36,662)	(41,563)	(47,420)	(42,504)	87,177	294,160	516,212	1,244,445
GAAP-EPS	(0.50)	(0.19)	(0.12)	(0.12)	(0.07)	(0.50)	(0.41)	(0.40)	(0.40)	(0.41)	(0.44)	(0.40)	0.81	2.72	4.75	11.41
GAAP EPS (dil)	(0.50)	(0.16)	(0.11)	(0.10)	(0.06)	(0.43)	(0.31)	(0.30)	(0.29)	(0.30)	(0.34)	(0.30)	0.61	2.07	3.61	8.67
Wgtd Avg Shrs (Bas) '000	47,952	49,471	54,207	54,749	55,297	53,431	70,457	80,755	91,093	102,719	106,892	107,320	107,750	108,182	108,615	109,050
Wgtd Avg Shrs (Dil) '000	47,952	57,471	62,287	62,910	63,539	61,552	93,743	109,141	124,601	136,361	140,669	141,232	141,798	142,366	142,936	143,509

Source: Dawson James estimates, company reports

Companies mentioned in this report:

Important Disclosures:

Price Chart:



Price target and ratings changes over the past three years:

- Initiated – Buy – January 30, 2023 – Price Target \$3.00
- Update Report – Buy – February 23, 2023 – Price Target \$3.00
- Update Report - Buy – March 2, 2023 – Price Target \$3.00
- Update Report - Buy – May 30, 2023 – Price Target \$3.00
- Update Report - Buy – June 27, 2023 – Price Target \$3.00

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of June 22, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "Valuation" and "Risk Analysis" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months.
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months.
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 22-Jun-23

	Company Coverage		Investment Banking	
Ratings Distribution	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	26	72%	2	5.50%
Market Perform (Neutral)	10	28%	2	5.50%
Market Underperform (Sell)	0	0%	0	0.00%
Total	36	100%	4	11.00%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.